Application of radiomics in precise diagnosis, efficacy evaluation, and treatment plan optimization of liver cancer

doi:10.3877/cma.j.issn.2095-3232.2026.02.006

Abstract

Abstract:

Primary liver cancer (PLC) is one of the most common malignant tumors, with high morbidity and mortality rates among all cancers. Radiomics is an interdisciplinary subject that performs high-throughput feature extraction from medical images combined with clinical data, which can be applied in diagnosis, prognostic prediction and treatment decision-making. In this article, the latest progress in radiomics in diagnosis and comprehensive treatment of PLC was systematically reviewed, such as early and accurate diagnosis,predicting microvessel invasion (MVI) and metastasis and recurrence, promoting individualized treatment and optimizing multidisciplinary team (MDT) diagnosis and treatment decision-making and integrating with molecular biology and artificial intelligence (AI) technologies. The challenges and development prospects of radiomics were also discussed.

Key words: Radiomics, Primary liver cancer, Prognostic assessment, Artificial intelligence, Precision diagnosis and treatment

Yufei Deng, Zhixin Wang, Ke Lou, Linxuan Zhang, Guichun Ma, Cuo Gang. Application of radiomics in precise diagnosis, efficacy evaluation, and treatment plan optimization of liver cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(02): 172-180.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2026.02.006

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2026/V15/I02/172

References 65

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.DOI: 10.3322/caac.21834.
[2]	滕熠, 张晓丹, 夏昌发, 等. 中国与全球癌症发病、死亡和患病对比及其预测分析: GLOBOCAN 2022数据解读[J]. 中华肿瘤防治杂志, 2024, 31(23): 1413-1420.
[3]	Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78(6): 1922-1965.DOI: 10.1097/HEP.0000000000000466.
[4]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(4): 407-449.DOI: 10.3877/cma.j.issn.2095-3232.2024.04.001.
[5]	Coffman-D'Annibale K, Xie C, Hrones DM, et al. The current landscape of therapies for hepatocellular carcinoma[J].Carcinogenesis, 2023, 44(7): 537-548.DOI: 10.1093/carcin/bgad052.
[6]	Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362.DOI: 10.1016/S0140-6736(22)01200-4.
[7]	Granata V, Fusco R, Setola SV, et al. An update on radiomics techniques in primary liver cancers[J]. Infect Agent Cancer, 2022, 17(1): 6.DOI: 10.1186/s13027-022-00422-6.
[8]	Bo Z, Song J, He Q, et al. Application of artificial intelligence radiomics in the diagnosis, treatment, and prognosis of hepatocellular carcinoma[J]. Comput Biol Med, 2024, 173: 108337.DOI: 10.1016/j.compbiomed.2024.108337.
[9]	McCague C, Ramlee S, Reinius M, et al. Introduction to radiomics for a clinical audience[J]. Clin Radiol, 2023, 78(2): 83-98.DOI: 10.1016/j.crad.2022.08.149.
[10]	Avery E, Sanelli PC, Aboian M, et al. Radiomics: a primer on processing workflow and analysis[J]. Semin Ultrasound CT MR, 2022, 43(2): 142-146.DOI: 10.1053/j.sult.2022.02.003.
[11]	刘伟, 高续, 谢玉海, 等. 基于增强CT影像组学模型在预测急性胰腺炎复发中的应用价值[J/OL].中华消化病与影像杂志（电子版）,2024,14(4)：348-354. DOI: 10.3877/cma.j.issn.2095-2015.2024.04.012.
[12]	Zhang W, Guo Y, Jin Q. Radiomics and its feature selection: a review[J]. Symmetry, 2023, 15(10): 1834.DOI: 10.3390/sym15101834.
[13]	Avanzo M, Wei L, Stancanello J, et al. Machine and deep learning methods for radiomics[J]. Med Phys, 2020, 47(5): e185-e202.DOI: 10.1002/mp.13678.
[14]	Demircioğlu A. Are deep models in radiomics performing better than generic models? A systematic review[J]. Eur Radiol Exp, 2023, 7(1): 11.DOI: 10.1186/s41747-023-00325-0.
[15]	Jiang C, Cai YQ, Yang JJ, et al. Radiomics in the diagnosis and treatment of hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2023, 22(4): 346-351.DOI: 10.1016/j.hbpd.2023.03.010.
[16]	Fusco R, Granata V, Setola SV, et al. The application of radiomics in cancer imaging with a focus on lung cancer, renal cell carcinoma, gastrointestinal cancer, and head and neck cancer: a systematic review[J]. Phys Med, 2025, 130: 104891.DOI: 10.1016/j.ejmp.2025.104891.
[17]	Harding-Theobald E, Louissaint J, Maraj B, et al. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2021, 54(7): 890-901.DOI: 10.1111/apt.16563.
[18]	Tang VH, Duong STM, Nguyen CDT, et al. Wavelet radiomics features from multiphase CT images for screening hepatocellular carcinoma: analysis and comparison[J]. Sci Rep, 2023, 13(1): 19559.DOI: 10.1038/s41598-023-46695-8.
[19]	Ma Y, Gong Y, Qiu Q, et al. Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma[J]. BMC Cancer, 2024, 24(1): 363.DOI: 10.1186/s12885-024-12109-9.
[20]	Castaldo A, De Lucia DR, Pontillo G, et al. State of the art in artificial intelligence and radiomics in hepatocellular carcinoma[J]. Diagnostics, 2021, 11(7): 1194.DOI: 10.3390/diagnostics11071194.
[21]	Hamm CA, Wang CJ, Savic LJ, et al. Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI[J]. Eur Radiol, 2019, 29(7): 3338-3347.DOI: 10.1007/s00330-019-06205-9.
[22]	林康强, 喻亚群. 实体肿瘤治疗疗效评估系统的发展及其在肝癌靶向治疗中的应用现状[J]. 中国普通外科杂志, 2022, 31(7): 958-965.DOI: 10.7659/j.issn.1005-6947.2022.07.013.
[23]	Pang B, Zuo B, Huang L, et al. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma[J]. Int Immunopharmacol, 2024, 137: 112492.DOI: 10.1016/j.intimp.2024.112492.
[24]	Zhang M, Kuang B, Zhang J, et al. Enhancing prognostic prediction in hepatocellular carcinoma post-TACE: a machine learning approach integrating radiomics and clinical features[J]. Front Med, 2024, 11: 1419058.DOI: 10.3389/fmed.2024.1419058.
[25]	Deng K, Chen T, Leng Z, et al. Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Radiol Med, 2024, 129(8): 1099-1117.DOI: 10.1007/s11547-024-01840-9.
[26]	Bai H, Meng S, Xiong C, et al. Preoperative CECT-based radiomic signature for predicting the response of transarterial chemoembolization (TACE) therapy in hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2022, 45(10): 1524-1533.DOI: 10.1007/s00270-022-03221-z.
[27]	Zhao Y, Wang N, Wu J, et al. Radiomics analysis based on contrast-enhanced MRI for prediction of therapeutic response to transarterial chemoembolization in hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 582788.DOI: 10.3389/fonc.2021.582788.
[28]	Sun Z, Shi Z, Xin Y, et al. Contrast-enhanced CT imaging features combined with clinical factors to predict the efficacy and prognosis for transarterial chemoembolization of hepatocellular carcinoma[J]. Acad Radiol, 2023, 30: S81-S91.DOI: 10.1016/j.acra.2022.12.031.
[29]	Zhou M, Zhang P, Mao Q, et al. Multisequence MRI-based radiomic features combined with inflammatory indices for predicting the overall survival of HCC patients after TACE[J]. J Hepatocell Carcinoma, 2024, 11: 2049-2061.DOI: 10.2147/JHC.S481301.
[30]	Kuang F, Gao Y, Zhou Q, et al. MRI radiomics combined with clinicopathological factors for predicting 3-year overall survival of hepatocellular carcinoma after hepatectomy[J]. J Hepatocell Carcinoma, 2024, 11: 1445-1457.DOI: 10.2147/JHC.S464916.
[31]	Liu F, Liu D, Wang K, et al. Deep learning radiomics based on contrast-enhanced ultrasound might optimize curative treatments for very-early or early-stage hepatocellular carcinoma patients[J]. Liver Cancer, 2020, 9(4): 397-413.DOI: 10.1159/000505694.
[32]	Hagiwara S, Nishida N, Kudo M. Advances in immunotherapy for hepatocellular carcinoma[J]. Cancers, 2023, 15(7): 2070.DOI: 10.3390/cancers15072070.
[33]	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7: 6.DOI: 10.1038/s41572-020-00240-3.
[34]	Chen Y, Yang C, Sheng L, et al. The era of immunotherapy in hepatocellular carcinoma: the new mission and challenges of magnetic resonance imaging[J]. Cancers, 2023, 15(19): 4677.DOI: 10.3390/cancers15194677.
[35]	Cui H, Zeng L, Li R, et al. Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma[J]. Clin Radiol, 2023, 78(2): e37-e44.DOI: 10.1016/j.crad.2022.09.113.
[36]	Moriguchi M, Kataoka S, Itoh Y. Evolution of systemic treatment for hepatocellular carcinoma: changing treatment strategies and concepts[J]. Cancers, 2024, 16(13): 2387.DOI: 10.3390/cancers16132387.
[37]	Hua Y, Sun Z, Xiao Y, et al. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy[J]. J Immunother Cancer, 2024, 12(7): e008953.DOI: 10.1136/jitc-2024-008953.
[38]	Li Y, Li X, Xiao X, et al. A novel hybrid model for predicting tertiary lymphoid structures and targeted immunotherapy outcomes in hepatocellular carcinoma: a multicenter retrospective study[J]. Eur Radiol, 2025, 35(6): 3206-3222.DOI: 10.1007/s00330-024-11255-9.
[39]	Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma[J]. Ann Surg Oncol, 2019, 26(5): 1474-1493.DOI: 10.1245/s10434-019-07227-9.
[40]	Lei Y, Feng B, Wan M, et al. Predicting microvascular invasion in hepatocellular carcinoma with a CT-and MRI-based multimodal deep learning model[J]. Abdom Radiol, 2024, 49(5): 1397-1410.DOI: 10.1007/s00261-024-04202-1.
[41]	Fu S, Pan M, Zhang J, et al. Deep learning-based prediction of future extrahepatic metastasis and macrovascular invasion in hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 1065-1076.DOI: 10.2147/JHC.S319639.
[42]	Chan LWC, Wong SCC, Cho WCS, et al. Primary tumor radiomic model for identifying extrahepatic metastasis of hepatocellular carcinoma based on contrast enhanced computed tomography[J]. Diagnostics, 2022, 13(1): 102.DOI: 10.3390/diagnostics13010102.
[43]	Zhao JW, Shu X, Chen XX, et al. Prediction of early recurrence of hepatocellular carcinoma after liver transplantation based on computed tomography radiomics nomogram[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(6): 543-550.DOI: 10.1016/j.hbpd.2022.05.013.
[44]	Zhou G, Zhou Y, Xu X, et al. MRI-based radiomics signature: a potential imaging biomarker for prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma[J]. Abdom Radiol, 2024, 49(1): 49-59.DOI: 10.1007/s00261-023-04049-y.
[45]	Ren L, Chen DB, Yan X, et al. Bridging the gap between imaging and molecular characterization: current understanding of radiomics and radiogenomics in hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2024, 11: 2359-2372.DOI: 10.2147/JHC.S423549.
[46]	Liao H, Jiang H, Chen Y, et al. Predicting genomic alterations of phosphatidylinositol-3 kinase signaling in hepatocellular carcinoma: a radiogenomics study based on next-generation sequencing and contrast-enhanced CT[J]. Ann Surg Oncol, 2022.DOI: 10.1245/s10434-022-11505-4.
[47]	Wen H, Liang R, Liu X, et al. Predicting pathological response of neoadjuvant conversion therapy for hepatocellular carcinoma patients using CT-based radiomics model[J]. J Hepatocell Carcinoma, 2024, 11: 2145-2157.DOI: 10.2147/JHC.S487370.
[48]	Li S, Dai Y, Chen J, et al. MRI-based habitat imaging in cancer treatment: current technology, applications, and challenges[J]. Cancer Imaging, 2024, 24(1): 107.DOI: 10.1186/s40644-024-00758-9.
[49]	Zhang M, Li Z, Yin Y. Analysis of treatment response based on 1. 5T magnetic resonance imaging texture analysis in stereotactic body radiotherapy of hepatocellular carcinoma[J]. J Radiat Res Appl Sci, 2024, 17(1): 100759.DOI: 10.1016/j.jrras.2023.100759.
[50]	Gu J, Bao S, Akemuhan R, et al. Radiomics based on contrast-enhanced CT for recognizing c-met-positive hepatocellular carcinoma: a noninvasive approach to predict the outcome of sorafenib resistance[J]. Mol Imaging Biol, 2023, 25(6): 1073-1083.DOI: 10.1007/s11307-023-01870-1.
[51]	Wu J, Mayer AT, Li R. Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy[J]. Semin Cancer Biol, 2022, 84: 310-328.DOI: 10.1016/j.semcancer.2020.12.005.
[52]	Wang W, Gu D, Wei J, et al. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI[J]. Eur Radiol, 2020, 30(5): 3004-3014.DOI: 10.1007/s00330-019-06585-y.
[53]	Wu HY, Cao SY, Xu ZG, et al. Construction of a radiogenomic signature based on endoplasmic reticulum stress for predicting prognosis and systemic combination therapy response in hepatocellular carcinoma[J]. BMC Cancer, 2025, 25(1): 131.DOI: 10.1186/s12885-025-13433-4.
[54]	Gu Y, Huang H, Tong Q, et al. Multi-view radiomics feature fusion reveals distinct immuno-oncological characteristics and clinical prognoses in hepatocellular carcinoma[J]. Cancers, 2023, 15(8): 2338.DOI: 10.3390/cancers15082338.
[55]	Mostafa G, Mahmoud H, Abd El-Hafeez T, et al. The power of deep learning in simplifying feature selection for hepatocellular carcinoma: a review[J]. BMC Med Inform Decis Mak, 2024, 24(1): 287.DOI: 10.1186/s12911-024-02682-1.
[56]	Wang Y, Zhang Y, Xiao J, et al. Multicenter integration of MR radiomics, deep learning, and clinical indicators for predicting hepatocellular carcinoma recurrence after thermal ablation[J]. J Hepatocell Carcinoma, 2024, 11: 1861-1874.DOI: 10.2147/JHC.S482760.
[57]	Zhao Y, Wang S, Wang Y, et al. Deep learning radiomics based on contrast enhanced MRI for preoperatively predicting early recurrence in hepatocellular carcinoma after curative resection[J]. Front Oncol, 2024, 14: 1446386.DOI: 10.3389/fonc.2024.1446386.
[58]	Miao J, Xu S, Zou B, et al. ResNet based on feature-inspired gating strategy[J]. Multimed Tools Appl, 2022, 81(14): 19283-19300.DOI: 10.1007/s11042-021-10802-6.
[59]	Xie XY, Chen R. Research progress of MRI-based radiomics in hepatocellular carcinoma[J]. Front Oncol, 2025, 15: 1420599.DOI: 10.3389/fonc.2025.1420599.
[60]	Floca R, Bohn J, Haux C, et al. Radiomics workflow definition & challenges-German priority program 2177 consensus statement on clinically applied radiomics[J]. Insights Imaging, 2024, 15(1): 124.DOI: 10.1186/s13244-024-01704-w.
[61]	黄少坚, 梁汉标, 李清平, 等. 基于影像组学和临床特征构建肝癌新辅助/转化治疗后病理学完全缓解预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(6): 860-867.DOI: 10.3877/cma.j.issn.2095-3232.2025.06.008.
[62]	Xia T, Zhao B, Li B, et al. MRI-based radiomics and deep learning in biological characteristics and prognosis of hepatocellular carcinoma: opportunities and challenges[J]. J Magn Reson Imaging, 2024, 59(3): 767-783.DOI: 10.1002/jmri.28982.
[63]	Huang W, Pan Y, Wang H, et al. Delta-radiomics analysis based on multi-phase contrast-enhanced MRI to predict early recurrence in hepatocellular carcinoma after percutaneous thermal ablation[J]. Acad Radiol, 2024, 31(12): 4934-4945.DOI: 10.1016/j.acra.2024.06.002.
[64]	Ho LM, Lam SK, Zhang J, et al. Association of multi-phasic MR-based radiomic and dosimetric features with treatment response in unresectable hepatocellular carcinoma patients following novel sequential TACE-SBRT-immunotherapy[J]. Cancers, 2023, 15(4): 1105.DOI: 10.3390/cancers15041105.
[65]	Bakas S, Vollmuth P, Galldiks N, et al. Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice[J]. Lancet Oncol, 2024, 25(11): e589-e601.DOI: 10.1016/S1470-2045(24)00315-2.

Please choose a citation manager

Content to export